GoDaddy Inc. Reports Fourth Quarter and Fiscal Year 2025 Financial Results
- On Feb. 23, 2026 BioMarin announced full-year 2025 results and provided 2026 guidance, with revenues expected to be $3,325 to $3,425 million.
- VOXZOGO's sales surged, driving 17% total revenue growth in 2025, while Enzyme Therapies advanced 9%, supported by PALYNZIQ, and BioMarin expanded VOXZOGO CANOPY with five new indications.
- Full-Year GAAP results show a net loss of $ million, while non-GAAP results reported $47.7 million net income and a 16.5% gross margin for 2025.
- The acquisition of Amicus Therapeutics, expected to close in Q2'26, includes $3.7 billion in financing, and management expects a Non‑GAAP Operating Margin of approximately 40% for 2026, excluding the post-close impact.
- Upcoming regulatory dates include a PALYNZIQ U.S. PDUFA date on February 28, 2026, and other 1H'26 program milestones; the press release contains extensive forward‑looking statements subject to risks, BioMarin said.
60 Articles
60 Articles
GoDaddy Inc. Reports Fourth Quarter and Fiscal Year 2025 Financial Results
TEMPE, Ariz., Feb. 24, 2026 /PRNewswire/ -- GoDaddy Inc. (NYSE: GDDY) today reported fourth quarter and fiscal year 2025 financial results. To view the earnings release, earnings presentation and prepared remarks, please access the company's Investor Relations website at https://aboutus.godaddy.net/investor-relations/financials.
TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and…
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium






















